492 Results (Page 12 of 20)
US Markets Research Reports
US Age-Related Macular Degeneration Therapeutics Market Analysis
The US Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $4.536 Bn in 2022, and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to US $7.736 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, technological advancements, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others.
US Adult Malignant Glioma Therapeutics Market Analysis
The US Adult Glioma Therapeutics Market is valued at around $924 Mn in 2022 and is projected to reach $1.576 Bn by 2030, exhibiting a CAGR of 6.9% during the forecast period. The increasing prevalence of metastatic glioma, driven by demographic shifts, advancements in diagnostic tools, and a rise in glioblastoma cases, coupled with the promise of targeted therapies based on genetic mutations, less invasive treatment options, and growing public awareness, collectively fuel the expansion of the market. Key players in the US Adult Malignant Glioma Therapeutics Market include Bristol-Myers Squibb, Roche, Novartis, Optune, Inc., Novocure, Arbor Pharmaceuticals, Elekta AB and Varian Medical Systems, Inc. among others
US Actinic Keratosis Therapeutic Market Analysis
The projected growth of the US actinic keratosis therapeutic market is from $2.87 Bn in 2022 to $3.59 Bn by 2030, with a forecasted CAGR of 2.9% between 2022 and 2030. It is attributed to the presence of promising investigational candidates in the pipeline, the increased research and development initiatives by pharmaceutical companies aimed at introducing innovative treatment approaches for actinic keratosis and the market expansion, which is also expected to be fueled by a preference for non-invasive treatments. Major players in the US Actinic Keratosis Therapeutics Market encompass LEO Pharma, Bausch Health, Almirall, Galderma, Perrigo, Sun Pharmaceuticals, Biofrontera, 3M Canada, and others.
US Over The Counter (OTC) Pharmaceuticals Market Analysis
US over-the-counter (OTC) pharmaceuticals market size was valued at $57750 Mn in 2022 and is estimated to expand at a CAGR of 3.54% from 2022 to 2030 and will reach $76281.2 Mn in 2030. OTC are non-prescription medications and are a vital component of the healthcare system, offering consumers accessible solutions for a wide range of common health issues. The market is segmented by product type and distribution channel. The key market players are Johnson and Johnson Services Inc (USA), Bayer AG (Germany), Novartis AG (Switzerland) and others.
US Radiotherapy Market Analysis
The US radiotherapy market is projected to grow from $2.9 Bn in 2022 to $3.97 Bn by 2030, registering a CAGR of 4% during the forecast period of 2022-30. The market is primarily driven by factors such as increasing cancer prevalence, rising demand for non-invasive cancer treatments, and technological advancements in radiotherapy equipment. The US is one of the largest markets for radiotherapy globally, with a significant number of cancer treatment centers and a high level of investment in research and development. The key players in the US radiotherapy market include major medical device manufacturers and radiation therapy providers such as Varian Medical Systems, Elekta AB, Accuray Incorporated, and Siemens Healthineers.
US Orphan Diseases Drugs Market Analysis
The US Orphan Diseases Drugs are projected to grow from $65.02 Bn in 2022 to $123.05 Bn by 2030, registering a CAGR of 8.3% during the forecast period of 2022-30. Orphan drugs are very expensive and can be difficult to access for patients and their families. This high pricing is driven by the high cost of research and development, as well as the small patient population for these drugs. Alexion Pharmaceuticals is a biopharmaceutical company that specializes in developing treatments for rare and ultra-rare diseases, including a drug for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
US Neurology Drugs Market Analysis
This report presents a strategic analysis of the US Neurology Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the US Neurology Drugs Market, offering unmatched value, accuracy, and expert insights.
US Healthcare Reimbursement Market Analysis
The US healthcare reimbursement market is projected to grow from $2306 Bn in 2022 to $6440 Bn by 2030, registering a CAGR of 13.70% during the forecast period of 2022-30. Changes in healthcare policies and regulations, such as the Affordable Care Act (ACA) and the Medicare Access and CHIP Reauthorization Act (MACRA), are driving the adoption of new reimbursement models and payment strategies. Major health insurance companies in the US include UnitedHealth Group, Anthem, Aetna, Cigna, and Humana.
US HIV Therapeutics Market Analysis
By 2030, it is anticipated that the US HIV therapeutics market will reach a value of $6.36 Bn from $5.78 Bn in 2022, growing at a CAGR of 1.2% during 2022-2030. The market is primarily dominated by local players such as ViiV Healthcare, Merck & Co, and Bristol-Myers Squibb. The market is driven by innovation in research and development, increasing prevalence, and good governance. The HIV therapeutics market in the US is segmented by type, product, geography, end user, and distribution channel.
US Diabetes Drugs Market Analysis
The US diabetes drugs market size was valued at $25.94 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030 and will reach $35.78 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The US diabetes drug market will grow because the prevalence of diabetes in the US is a major driver of the market. There is a large and growing demand for diabetes medications, including insulin and oral medications, to manage the disease and prevent its complications. The key market players are Johnson & Johnson, Novo Nordisk, Novartis, Merck, Eli Lilly and Company, and others.
US Anti Aging Therapeutics Market Analysis
The US anti-aging therapeutics market is projected to grow from $0.3 Bn in 2022 to $0.8 Bn by 2030, registering a CAGR of 14.53% during the forecast period of 2022-30. The market is a rapidly growing sector that includes a variety of products and services aimed at reducing or reversing the effects of aging. The key players in the market include Allergan, Inc., Lumenis Ltd., Cynosure, Inc., Personal Microderm, Johnson & Johnson, and Alma Lasers, among others. These companies are investing heavily in research and development to develop new and innovative products to meet the growing demand for anti-aging products and services.
US 3D Imaging Market Analysis
The US 3D imaging market is projected to grow from $12.76 Bn in 2022 to $37.69 Bn by 2030, registering a CAGR of 14.5% during the forecast period of 2022-30. The market will be driven by the growing need for less invasive procedures & increased incidence of chronic conditions that require precise diagnostics. The market is segmented by product, application, end-user & portability. Some of the major players include GE Healthcare, Siemens Healthineers & Canon Medical Systems Corporation.
US Alzheimer’s Disease Drugs Market Analysis
The US Alzheimer’s disease drugs market was valued at $6.48 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.42% from 2022 to 2030 and will reach $10.65 Bn in 2030. One of the main reasons propelling the growth of this market is government support, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AstraZeneca, Biogen, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.
US Anemia Drugs Market Analysis
The US Anemia Drugs market was valued at $6.7 Bn in 2022 and is estimated to expand at a CAGR of 6.9% from 2022-30 and will reach $11.45 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic disease and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, Roche, Pfizer, Johnson & Johnson, Novartis, Takeda Pharmaceutical Co., Akebia Therapeutics, and FibroGen.
US Biosimilars Market Analysis
The US biosimilars market size was valued at $8.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.2% from 2022 to 2030 and will reach $35.1 Bn in 2030. The market is segmented by product type and indication type. The US biosimilars market will grow as chronic diseases including cancer and autoimmune conditions are more common and the demand for biosimilars is being fueled by the fact that they provide an affordable means of treating certain illnesses. The key market players are Pfizer (USA), Amgen (USA), Sandoz (CHE), Mylan (USA), and others.
US Multiple Myeloma Therapeutics Market Analysis
The US Multiple Myeloma Therapeutics Market was valued at $3.5 Bn in 2022 and is estimated to expand at a CAGR of 2.5% from 2022 to 2030 and will reach $4.26 Bn in 2030. One of the main reasons propelling the growth of this Market is advancements in therapeutic development and increased funding for research and development. The market is segmented by type, drug, and distribution channel. Some key players in this Market are Takeda Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, Amgen, AbbVie, Novartis, GlaxoSmithKline, Sanofi and others.
US Neurology Clinical Trials Market Analysis
The US neurology clinical trials market is projected to grow from $2.20 Bn in 2022 to $2.89 Bn by 2030, registering a CAGR of 3.5% during the forecast period of 2022-30. The prevalence of neurological disorders in the US is on the rise, with an aging population and changing lifestyles being significant contributors. As a result, there is a growing need for effective treatments and therapies to manage and treat these conditions, leading to an increase in neurology clinical trials. The US neurology clinical trials market is expected to grow significantly in the coming years, driven by an increasing prevalence of neurological disorders, a growing aging population, and advancements in technology and treatments.
US Clinical Trials Support Service Market Analysis
The US clinical trials support services market is projected to grow from $8.76 Bn in 2022 to $13.24 Bn by 2030, registering a CAGR of 5.3% during the forecast period of 2022-30. The high burden of infectious and chronic diseases in emerging economies, pharmaceutical companies' high R&D spending, an increase in the number of contract research organizations, and the prevalence of diseases are the main drivers of the market's expansion. The major key players in the market are Charles River Labs, Covance, Syneos Health, etc.
US Advanced Therapy Medicinal Products (ATMPs) Market Analysis
The US Advanced Therapy Medicinal Products (ATMPs) market is projected to grow from $4.3 Bn in 2022 to $9.8 Bn by 2030, registering a CAGR of 11% during the forecast period of 2022-30. One of the key drivers of growth in the US ATMP market is the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. These diseases often require long-term treatment, and ATMPs offer a promising new approach to treating them. Additionally, advances in gene editing technologies such as CRISPR/Cas9 have increased the potential for ATMPs to cure genetic disorders. Some of the major players are Novartis International AG, Gilead Sciences, Inc., Bluebird Bio, Inc., Spark Therapeutics, Inc., and Kite Pharma, Inc.
US Cancer Pain Management Market Analysis
The US cancer pain management market is projected to grow from $2.74 Bn in 2022 to $3.55 Bn by 2030, registering a CAGR of 3.33% during the forecast period of 2022-30. The main factors driving the growth would be increasing cancer incidence, the launch of new and advanced pain management drugs, government initiatives, and the growing need for non-invasive and minimally invasive pain management methods. The market is segmented by drug type and by disease. Some of the major players include Collegium Pharmaceutical (USA), Pfizer (USA), Abbott (USA), Sorrento Therapeutics (USA), Galena Biopharma (USA), Hisamitsu Pharmaceutical, Aoxing Pharmaceutical, Orexo, and Teva Pharmaceuticals.
US Acromegaly Therapeutics Market Analysis
US Acromegaly Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence and incidence of acromegaly and pituitary tumours are rising, as is global awareness of the disease. Technological advances in the development of new acromegaly medications are also key contributors to the market's growth. The high prevalence of hormonal problems, evolving lifestyles, and rising genetic disease incidence are all anticipated to fuel market expansion.Some of the key players in the global acromegaly therapeutics Market include Roche, Sanofi, GSK, Pfizer INC., Ipsen, Chiasma Inc, Validus pharmaceuticals LLC., Novartis AG, Amryt, Recordati, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals , and Others.
US Adrenoleukodystrophy (ALD) Therapeutics Market Analysis
US Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the US Adrenoleukodystrophy (ALD) drugs market.
US Alport Syndrome Therapeutics Market Analysis
US during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.
US Anal Fistula Therapeutics Market Analysis
US During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.
US Angelman Syndrome Therapeutics Market Analysis
US During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.